Literature DB >> 27785897

Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma.

Makiko Hino1, Yusuke Kobayashi2,3, Michiko Wada2, Yoshihisa Hattori2, Takashi Kurahasi2, Hiroyuki Nakagawa2.   

Abstract

There are many reports on paclitaxel, ifosfamide, and cisplatin (TIP) therapy, following standard bleomycin, etoposide, and cisplatin (BEP) therapy, for salvage treatment of testicular malignant germ cell tumors, but there are no reports on its use for ovarian malignant tumors. We report here that a patient with primary ependymoma of the ovary, who was resistant to BEP therapy, achieved a complete response to a combined therapy, including TIP therapy as the second-line chemotherapy and surgery. This important case, combined with published studies, suggests that TIP therapy is effective for both testicular and ovarian malignant tumors and indicates that TIP therapy can be used as an effective second-line therapy for malignant tumors resistant to BEP therapy.
© 2016 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  bleomycin, etoposide, and cisplatin; ependymoma; malignant germ cell tumors; paclitaxel, ifosfamide, and cisplatin; salvage

Mesh:

Substances:

Year:  2016        PMID: 27785897     DOI: 10.1111/jog.13084

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  3 in total

1.  A Rare Case of Metastatic Primary Peritoneal Ependymoma: A Case Report and Literature Review.

Authors:  Ben Man Fei Cheung; Johnny Kin Sang Lau; Anthony W I Lo; Mai-Yee Luk; Kwok Keung Yuen
Journal:  Case Rep Oncol Med       Date:  2020-08-14

2.  Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole.

Authors:  Justin Wayne Gorski; Jolyn Sharpe Taylor; Jing Zhang; Jinsong Liu; Amir Anthony Jazaeri
Journal:  Gynecol Oncol Rep       Date:  2017-03-14

Review 3.  Ovarian ependymoma presenting in pregnancy: a case report and literature review.

Authors:  Bo Jin; Jingjing Jiang; Hongfa Peng
Journal:  BMC Pregnancy Childbirth       Date:  2020-11-18       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.